Between July 6 and 9, 2026, the Bénin Agence du Médicament et des autres produits de Santé (ABMed) underwent a rigorous evaluation by a panel of experts from the World Health Organization (WHO). This meticulous assessment highlighted remarkable advancements, positioning Bénin on the cusp of achieving the coveted WHO Maturity Level 3 certification—a milestone that would cap nearly a decade of sweeping reforms in the health sector.

An exhaustive international audit of Bénin’s pharmaceutical framework

A four-day intensive inspection scrutinized every facet of Bénin’s pharmaceutical governance. A delegation of eight WHO specialists meticulously reviewed legal frameworks, operational protocols, and regulatory practices within the ABMed. The audit covered every critical aspect: drug market authorization, post-market surveillance, pharmacovigilance, and clinical trial oversight. The goal? To ensure full alignment with the most stringent international standards.

The findings, unveiled on July 9, 2026, in Cotonou, were overwhelmingly positive. The evaluation underscored significant progress, confirming that Bénin is on the brink of securing a robust and globally compliant pharmaceutical supply chain.

The significance of WHO Maturity Level 3

But what does this Maturity Level 3 (ML3) certification entail? According to WHO’s classification, it signifies a nation with a stable, fully operational, and integrated pharmaceutical regulatory system. Reaching this tier means the national authority can exercise complete control over medications circulating within its borders, ensuring public access to safe, high-quality, and efficacious health products.

Beyond safety, this WHO certification serves as a powerful economic and geopolitical asset. It bolsters international trust, encourages local drug manufacturing, and eases cross-border trade. For Bénin’s citizens, it represents a fortified defense against counterfeit medicines and a commitment to evidence-based healthcare.

A decade of reform culminating in success

The evaluation results were presented in the presence of Health Minister Professor Benjamin Hounkpatin, who expressed profound satisfaction with the findings. In his address, he commended the ABMed teams for their dedication and the transformative strides achieved.

This imminent recognition is no accident—it is the culmination of bold, systemic reforms initiated by the government in 2017. By restructuring the former pharmacy directorate into an autonomous agency (ABMed) and reinforcing legal frameworks, Bénin laid the groundwork for this qualitative leap. Minister Hounkpatin reaffirmed the state’s unwavering commitment to supporting ABMed until the final certification is secured.

Bénin poised to lead West Africa’s pharmaceutical governance

The stakes of this evaluation extend far beyond national borders. Should the final assessment confirm Bénin’s progression to Maturity Level 3, the country could become the second Francophone nation in West Africa to attain this global standard, following Sénégal.

This achievement would position Bénin as a future hub of excellence in health governance across the subregion. It also demonstrates that with strong political will and sustained technical rigor, African nations can align their institutions with the highest global benchmarks.

A new chapter in public health for Bénin

The July 2026 WHO mission marks a historic turning point for Bénin’s public health landscape. As all indicators turn green, ABMed must now redouble efforts to implement the remaining recommendations and formalize this status upgrade. By inching closer to Maturity Level 3, Bénin proves that patient safety and pharmaceutical sovereignty are not distant aspirations but an unfolding reality.